| 彭飞飞,贾 琳,张慧聪,武 蕾,宋 刚.清热化痰、宣肺解痉法治疗支气管哮喘的临床疗效及对气道呼吸参数、生活质量的影响[J].现代生物医学进展英文版,2024,(2):304-308. |
| 清热化痰、宣肺解痉法治疗支气管哮喘的临床疗效及对气道呼吸参数、生活质量的影响 |
| Clinical Effect of Clearing Heat, Resolving Phlegm, Dispersing Lung and Spasmolysis on Bronchial Asthma and Its Influence on Airway Rspiratory Parameters and Quality of Life |
| Received:March 27, 2023 Revised:April 24, 2023 |
| DOI：10.13241/j.cnki.pmb.2024.02.019 |
| 中文关键词: 支气管哮喘 清热化痰宣肺解痉法 气道呼吸参数 生活质量 |
| 英文关键词: Bronchial asthma Clearing heat, resolving phlegm, dispersing lung and spasmolysis Airway respiratory parameters Quality of life |
| 基金项目:河北省中医药管理局科研计划项目（2020025） |
|
| Hits: 364 |
| Download times: 295 |
| 中文摘要: |
| 摘要 目的：探讨清热化痰、宣肺解痉法治疗支气管哮喘的临床疗效及对气道呼吸参数、生活质量的影响。方法：选取我院2019年10月到2021年9月收治的60例支气管哮喘患者作为研究对象，分为观察组与对照组，每组30例。对照组予吸入布地奈德福莫特罗粉吸入剂，观察组在对照组基础上增加清热化痰宣肺解痉法治疗，对比两组患者临床疗效，治疗前与治疗1个月后的中医证候积分变化，气道呼吸参数变化，炎症因子以及生活质量变化。结果：观察组总有效率较对照组高（P<0.05）；两组患者治疗前中医证候积分对比无差异（P＞0.05），治疗后降低，且观察组低于对照组（P＜0.05）；两组患者治疗前第1秒用力呼气容积（FEV1）、用力肺活量（FVC）、第1s用力呼气量/用力肺活量（FEV1/FVC）最大呼气流速（PEF）对比无明显差异（P＞0.05），治疗后两组患者FVC、FEV1、FEV1/ FVC、PEF均有提升，且观察组高于对照组（P＜0.05）；两组患者治疗前肿瘤坏死因子-α（TNF-α）、转化生长因子-β1（TGF-β1）、基质金属蛋白-9（MMP-9）、血管内皮生长因子（VEGF）、干扰素-γ（IFN-γ）、白细胞介素-4（IL-4）水平对比无明显差异（P＞0.05），治疗后两组患者TNF-α、TGF-β1、MMP-9、VEGF、IFN-γ、IL-4水平均明显降低，且观察组低于对照组（P＜0.05）；两组患者治疗前生活质量评分对比无差异（P＞0.05），治疗后1个月生活质量相关评分均降低，且观察组较对照组低（P＜0.05）。结论：支气管哮喘患者在常规西医治疗基础上增加清热化痰宣肺解痉法治疗可减轻患者症状。另外可改善患者呼吸功能，降低炎症因子反应，提升患者生活质量。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the clinical effect of clearing heat, resolving phlegm, dispersing lung and spasmolysis on bronchial asthma and its influence on airway respiratory parameters and quality of life. Methods: 60 patients with bronchial asthma admitted to our hospital from October 2019 to September 2021 were selected as the study subjects. All patients were divided into observation group and matched group by random number table method, with 30 patients in each group. The matched group was given inhaled budeseide formoterol powder. The observation group was treated with the method of clearing heat, resolving phlegm, dispersing lung and spasmolysis on the basis of the matched group. The clinical effects of the two groups were compared, the changes of TCM syndrome integral, airway respiratory parameters, inflammatory factors and quality of life before and Post-treatment for 1 month. Results: The total effective rate of the observation group was higher than matched group (P<0.05); There was no difference in the scores of TCM syndromes between the two groups Pretherapy (P>0.05). Post-treatment, the two groups were lower, and the scores of the observation group were lower than those of the matched group (P<0.05); There was no difference between the two groups in the forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), forced expiratory volume/forced vital capacity in the first second (FEV1/FVC) and the maximum expiratory flow (PEF) in the first second (FEV1/FVC) Pretherapy (P>0.05) PEF increased, and the observation group was higher than the matched group (P<0.05); There were no difference in the pre-treatment tumor necrosis factor- α (TNF-α), transforming growth factor- β1 (TGF-β1), matrix metalloprotein-9 (MMP-9), Vascular endothelial growth factor (VEGF), interferon-γ (IFN-γ), and interleukin-4 (IL-4) (P>0.05). Post-treatment, TNF-α, TGF-β1, MMP-9, VE GF, IFN-γ, and IL-4 levels decreased, and the observed group was lower than the matched group (P<0.05); There was no difference in the scores of quality of life between the two groups Pretherapy (P>0.05). The scores of quality of life in the two groups were decreased 1 month Post-treatment , and the scores in the observation group were lower than those in the matched group (P<0.05). Conclusion: Patients with bronchial asthma on the basis of conventional western medicine treatment by increasing phlegm and pulmonary spasmodiysis can reduce the symptoms. In addition, it can improve the respiratory function of patients, reduce the inflammatory factor response, and improve the quality of life of patients. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
